Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) is set to announce its fourth quarter and full year 2022 financial results on February 23, 2023, after the U.S. market closes. A conference call will follow at 4:30 p.m. ET. Investors can access the live audio webcast through the company's website. Dynavax focuses on developing and commercializing innovative vaccines. Its notable products include HEPLISAV-B for Hepatitis B prevention and CpG 1018, used in various COVID-19 vaccines. The company aims to advance its position through global collaborations.

Positive

• Dynavax will report 2022 financial results, indicating ongoing business transparency.
• The company has two commercial products, HEPLISAV-B and CpG 1018, which are critical to its revenue stream.

Negative

• The press release does not provide any specific financial metrics or guidance, leaving uncertainty regarding performance.

EMERYVILLE, Calif., Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the U.S. financial markets close.

Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Dynavax will host a conference call and live audio webcast on Thursday, February 23, 2023, at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.

Contacts:
Nicole Arndt
Investor Relations and Corporate Communications
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-call-on-february-23-2023-301743397.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its fourth quarter 2022 financial results?

Dynavax will report its fourth quarter 2022 financial results on February 23, 2023.

What time is the Dynavax conference call scheduled?

The Dynavax conference call is scheduled for February 23, 2023, at 4:30 p.m. ET.

How can I access the Dynavax financial results webcast?

The webcast can be accessed through the 'Events & Presentations' page in the Investors section of the Dynavax website.

What products does Dynavax currently commercialize?

Dynavax commercializes HEPLISAV-B for Hepatitis B and CpG 1018 adjuvant for various vaccines.